Spinifex Pharmaceuticals is an Australian biotechnology company developing new drug candidates for the treatment and management of pain.
Established in 2005 and based in Melbourne, Spinifex has applied its world-class drug development capabilities to advance product candidates. Its lead product EMA401 is under development as a potential first-in-class oral treatment for chronic pain, including neuropathic pain, without CNS side effects. Spinifex's Phase 2 program for EMA401 includes clinical trials in a number of neuropathic pain conditions. Spinifex investors are GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest.
For more information please contact:Company Dr Tom McCarthy CEO Spinifex Pharmaceuticals Tel: +61(0)3-9938-1205 Email: firstname.lastname@example.org Media Chris Gardner/ Nina Enegren Citigate Dewe Rogerson Tel: +44(0)20-7638-9571 Email: email@example.com SOURCE Spinifex Pharmaceuticals